CorMedix Inc.
CRMD evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $620.4M
- Lead Asset:
- DefenCath (Phase 4)
What it means
What to watch
Prepared research question
What matters most for CRMD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRMD
CorMedix Inc. is a biopharmaceutical company that commercializes DefenCath® and a diversified portfolio of hospital-focused specialty pharmaceuticals following its August 2025 acquisition of Melinta Therapeutics LLC.
Key risk: Product adoption and reimbursement
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial · 2 catalysts · 1 FDA decision for CorMedix Inc..
CorMedix Inc. is a biopharmaceutical company that commercializes DefenCath® and a diversified portfolio of hospital-focused specialty pharmaceuticals following its August 2025 acquisition of Melinta Therapeutics LLC.
- Cash & equivalents of $256.7M as of 2026-06-30 [sec].
- Total revenue of $101.9M and net income of $26.0M as of 2026-06-30 [sec].
- Commercializes DefenCath® and a diversified portfolio including MINOCIN, REZZAYO, VABOMERE, ORABACTIV, BAXDELA, KIMYRSA, and TOPROL-XL following the August 2025 Melinta acquisition [sec · filed 2026-04-29].
- REZZAYO (rezafungin acetate) is in Phase 3 for prophylaxis of invasive fungal infections; Mundipharma holds the NDA and will transfer rights to CorMedix by June 30, 2028 [pipeline].
- DefenCath (heparin sodium; taurolidine) is in Phase 4 for reduction of CLABSI in TPN patients [pipeline].
What works
- Diversified commercial portfolio of six specialty injectable products plus DefenCath, reducing reliance on a single product [sec · filed 2026-04-29].
- Strong cash position of $256.7M as of 2026-06-30 provides financial flexibility for operations and growth [sec].
- Positive Phase III topline results for REZZAYO and raised full-year net revenue guidance to $325M–$345M in May 2026 [news · published 2026-05-17].
What to weigh
- Results are affected by timing and pace of product adoption, reimbursement dynamics, and cost optimization execution [sec_mda · as of 2026-08-13].
- Interest expense from convertible senior notes and investments in commercial infrastructure impact financial results [sec_mda · as of 2026-08-13].
- General economic conditions, geopolitical developments, and competitive pressures could affect product performance [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
CorMedix commercializes a diversified portfolio following the Melinta acquisition.
“Following the August 2025 acquisition of Melinta, we are now commercializing a diversified portfolio of specialty pharmaceuticals utilized predominantly in institutional settings of care, including MINOCIN ® (minocycline) for Injection, REZZAYO ® (rezafungin for injection), VABOMERE ® (meropenem and vaborbactam), ORABACTIV™ (oritavancin), BAXDELA ® (delafloxacin), and KIMYRSA ® (oritavancin), as well as TOPROL -XL ® (metoprolol succinate).”
SEC filings · April 29, 2026
REZZAYO Phase 3 topline results were positive and full-year net revenue guidance was raised.
“CorMedix highlighted positive Phase III topline results for REZZAYO and ongoing progress in its late-stage anti-infective pipeline, underscoring how clinical developments are beginning to align with its expanded commercial footprint.”
News · May 17, 2026
Mundipharma will transfer REZZAYO NDA rights to CorMedix by June 30, 2028.
“upon the earlier of thirty-days following the receipt of the marketing approval for the prophylaxis indication or on June 30, 2028, Mundipharma shall assign and transfer to CorMedix all rights, title and interest in and to the U.S. NDA and sNDAs for REZZAYO.”
DefenCath is in Phase 4 for CLABSI reduction in TPN patients.
“DefenCath Generic Name: HEPARIN SODIUM; TAUROLIDINE Indication: reduction of central line associated bloodstream infection (CLABSI) in adult patients receiving total parental nutrition (TPN) Phase: Phase 4”
Catalyst timeline
- 2038-07-14 · Patent_Expiry · REZAFUNGIN ACETATE — Patent expiry for REZZAYO (rezafungin acetate) NDA217417; may affect market exclusivity.
- 2042-04-15 · Patent_Expiry · HEPARIN SODIUM; TAUROLIDINE — Patent expiry for DefenCath (heparin sodium; taurolidine) NDA214520; may affect market exclusivity.
Risks & what to watch (3)›
Key risks
- Product adoption and reimbursement — Results may be affected by timing and pace of product adoption and reimbursement dynamics [sec_mda · as of 2026-08-13].
- Interest expense from debt — Interest expense from convertible senior notes impacts financial results [sec_mda · as of 2026-08-13].
- Competitive and economic pressures — General economic conditions, tariffs, and competition could affect product performance [sec_mda · as of 2026-08-13].
What to watch
- Integration and performance of the Melinta portfolio [sec_mda · as of 2026-08-13].
- REZZAYO Phase 3 data and potential NDA transfer from Mundipharma by June 30, 2028 [pipeline].
- DefenCath Phase 4 progress for CLABSI reduction in TPN patients [pipeline].
- Full-year 2026 net revenue guidance of $325M–$345M and subsequent financial results [news · published 2026-05-17].
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run CorMedix Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available CorMedix Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.96 · 18% dilution
Lead: Phase 3
2 candidates
2 upcoming, next in ~4291d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 21.0%
- Days to cover
- 16.0
- Shares short
- 16,222,947
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRMD short interestGovernance
Frequently asked questions
What is the AI investment thesis for CorMedix Inc.?
CorMedix Inc. is a biopharmaceutical company that commercializes DefenCath® and a diversified portfolio of hospital-focused specialty pharmaceuticals following its August 2025 acquisition of Melinta Therapeutics LLC.
What is CorMedix Inc.'s lead drug candidate?
CorMedix Inc.'s most advanced tracked candidate is DefenCath (Phase 4) for reduction of central line associated bloodstream infection (CLABSI) in adult patients receiving total parental nutrition (TPN).
What is CorMedix Inc.'s next catalyst?
CorMedix Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA217417" — expected July 14, 2038.
Who is the CEO of CorMedix Inc.?
Mr. Joseph Todisco MBA is the chief executive officer of CorMedix Inc. (CRMD).
Where is CorMedix Inc. headquartered?
CorMedix Inc. (CRMD) is headquartered in Parsippany, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.